Charles R Esther1, Wanda K O'Neal2, Wayne H Anderson2, Mehmet Kesimer2, Agathe Ceppe2, Claire M Doerschuk2, Neil E Alexis2, Annette T Hastie3, R Graham Barr4, Russell P Bowler5, J Michael Wells6, Elizabeth C Oelsner4, Alejandro P Comellas7, Yohannes Tesfaigzi8, Victor Kim9, Laura M Paulin10, Christopher B Cooper11, MeiLan K Han12, Yvonne J Huang12, Wassim W Labaki12, Jeffrey L Curtis13, Richard C Boucher2. 1. Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: charles_esther@med.unc.edu. 2. Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC. 3. Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, NC. 4. Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY. 5. Department of Medicine, National Jewish Health, Denver, CO. 6. Lung Health Center, Division of Pulmonary Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL. 7. Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA. 8. Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 9. Pulmonary and Critical Care Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. 10. Department of Medicine and Epidemiology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Hanover, NH. 11. Department of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. 12. Division of Pulmonary and Critical Care Medicine, University of Michigan Ann Arbor, Ann Arbor, MI. 13. Division of Pulmonary and Critical Care Medicine, University of Michigan Ann Arbor, Ann Arbor, MI; Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Abstract
BACKGROUND: Improved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets. RESEARCH QUESTION: Which physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations? STUDY DESIGN AND METHODS: We applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations. RESULTS: Sputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations. INTERPRETATION: Biomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.
BACKGROUND: Improved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets. RESEARCH QUESTION: Which physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations? STUDY DESIGN AND METHODS: We applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations. RESULTS: Sputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations. INTERPRETATION: Biomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.
Authors: David Couper; Lisa M LaVange; MeiLan Han; R Graham Barr; Eugene Bleecker; Eric A Hoffman; Richard Kanner; Eric Kleerup; Fernando J Martinez; Prescott G Woodruff; Stephen Rennard Journal: Thorax Date: 2013-09-12 Impact factor: 9.139
Authors: Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-12-28 Impact factor: 3.000
Authors: Olaf Eickmeier; Marisa Huebner; Eva Herrmann; Ulrich Zissler; Martin Rosewich; Patrick C Baer; Roland Buhl; Sabina Schmitt-Grohé; Stefan Zielen; Ralf Schubert Journal: Cytokine Date: 2010-02-23 Impact factor: 3.861
Authors: G Paone; V Leone; V Conti; L De Marchis; E Ialleni; C Graziani; M Salducci; M Ramaccia; G Munafò Journal: Eur Rev Med Pharmacol Sci Date: 2016 Impact factor: 3.507
Authors: Ashley G Henderson; Camille Ehre; Brian Button; Lubna H Abdullah; Li-Heng Cai; Margaret W Leigh; Genevieve C DeMaria; Hiro Matsui; Scott H Donaldson; C William Davis; John K Sheehan; Richard C Boucher; Mehmet Kesimer Journal: J Clin Invest Date: 2014-06-02 Impact factor: 14.808
Authors: Peter A Keyel; Matthew Romero; Wenbo Wu; Daniel H Kwak; Qin Zhu; Xinyu Liu; Russell D Salter Journal: PLoS One Date: 2014-08-12 Impact factor: 3.240
Authors: Liuyang Wang; Emily R Ko; James J Gilchrist; Kelly J Pittman; Anna Rautanen; Matti Pirinen; J Will Thompson; Laura G Dubois; Raymond J Langley; Sarah L Jaslow; Raul E Salinas; D Clayburn Rouse; M Arthur Moseley; Salim Mwarumba; Patricia Njuguna; Neema Mturi; Thomas N Williams; J Anthony G Scott; Adrian V S Hill; Christopher W Woods; Geoffrey S Ginsburg; Ephraim L Tsalik; Dennis C Ko Journal: Sci Adv Date: 2017-03-08 Impact factor: 14.136